FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

For research purposes only. Full disclaimer →

مكتبة البروتيدات

SLU-PP-332

ERR alpha agonist

Weight Loss & Metabolic

SLU-PP-332 is a small molecule agonist of the estrogen-related receptors (ERRs), particularly ERR-alpha and ERR-gamma, developed at Saint Louis University as an exercise mimetic that enhances muscle endurance and fatigue resistance without physical training. It is not technically a peptide but a synthetic small molecule that activates transcription factors controlling mitochondrial biogenesis, oxidative metabolism, and muscle fiber type composition. Published in 2023, it represents one of the newest entries in the exercise mimetic compound class and remains in very early preclinical development.

mechanism of action

ERRa agonist that mimics the transcriptional effects of exercise. Activates mitochondrial biogenesis and oxidative metabolism pathways.

Research Protocols

للاستخدام البحثي فقط. ليس مشورة طبية.

Research protocols limited to animal studies. Mouse models used 25-50mg/kg. No established human dosing.

Research Notes

Clinical Research Status

SLU-PP-332 was first published in the Journal of Pharmacology and Experimental Therapeutics in 2023 by researchers at Saint Louis University, representing extremely early-stage preclinical research with only animal data available. No clinical trials have been registered or planned for human testing, and the compound remains purely a research tool for understanding ERR biology and exercise physiology. Its emergence has generated media attention as a potential "exercise in a pill" compound, though such applications remain speculative and distant from clinical reality.

Key Published Findings

Mouse studies demonstrate that SLU-PP-332 administration increased running endurance by approximately 50% on treadmill exhaustion tests and enhanced fatigue-resistant oxidative (Type I and IIa) muscle fiber proportions without exercise training. The compound activates ERR-alpha and ERR-gamma transcription factors, which are master regulators of mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation gene programs in skeletal muscle. Treated animals showed increased muscle mitochondrial density, enhanced oxidative capacity, and gene expression profiles resembling those of trained athletes.

Safety Profile

Formal toxicology studies have not been published, and the safety profile of SLU-PP-332 in any species is largely unknown beyond the limited animal experiments reported. ERR receptors are expressed in multiple tissues including heart, kidney, and brain, raising theoretical concerns about off-target effects from systemic ERR activation. The structural novelty of the compound means there is no existing clinical safety data from related molecules to extrapolate from, unlike older exercise mimetics with more established safety profiles.

Comparison to Related Compounds

SLU-PP-332 targets a different pathway than AICAR (AMPK activation) or GW501516 (PPAR-delta activation), representing a third distinct molecular approach to exercise mimicry through the ERR transcription factor family. While GW501516 demonstrated concerning carcinogenicity in long-term animal studies, whether ERR agonism carries similar risks is unknown due to the early stage of research. Unlike both AICAR and GW501516 which have years of research history and some human data, SLU-PP-332 has only a single primary publication and minimal characterization.

Community Observations

Interest in SLU-PP-332 has been driven primarily by mainstream media coverage framing it as an "exercise pill," generating excitement in fitness and longevity communities. The compound is not commercially available from any legitimate source as of current reports, and anyone claiming to sell it likely cannot verify identity or purity. Experienced researchers in the performance enhancement space advise patience, noting that the journey from initial publication to any form of human-ready compound typically spans 10-15 years of development.

Half Life

~4-6 hours

Reconstitution

DMSO or appropriate vehicle

Storage

Lyophilized

Store at -20C. Protect from light and moisture.

Reconstituted

Store at -20C in solution.

US Legal Status

Research chemical (not FDA-approved)

Also Known As

ERR alpha agonist

الأسئلة الشائعة

ما هو SLU-PP-332؟

SLU-PP-332 is a small molecule agonist of the estrogen-related receptors (ERRs), particularly ERR-alpha and ERR-gamma, developed at Saint Louis University as an exercise mimetic that enhances muscle endurance and fatigue resistance without physical training. It is not technically a peptide but a synthetic small molecule that activates transcription factors controlling mitochondrial biogenesis, oxidative metabolism, and muscle fiber type composition. Published in 2023, it represents one of the newest entries in the exercise mimetic compound class and remains in very early preclinical development.

كيف يعمل SLU-PP-332؟

ERRa agonist that mimics the transcriptional effects of exercise. Activates mitochondrial biogenesis and oxidative metabolism pathways.

ما هو الوضع التنظيمي لـ SLU-PP-332 في الولايات المتحدة؟

Research chemical (not FDA-approved)

ما هو عمر النصف لـ SLU-PP-332؟

~4-6 hours

ما الأسماء الأخرى لـ SLU-PP-332؟

ERR alpha agonist

Peptide Contacts provides research-based summaries for informational purposes only. We do not host, distribute, or endorse vendor documentation. All certificates of analysis, GMP certificates, and vendor communications must be requested and verified directly by the buyer. Nothing on this platform constitutes legal, medical, or professional advice. Users are solely responsible for verifying vendor credentials and ensuring compliance with all applicable local, state, and federal laws before purchasing any research chemicals. Use of this platform constitutes acceptance of full personal responsibility.

Read full disclaimer